Dongcheng Pharmaceutical's subsidiary, Yantai Dongcheng Northern Pharmaceutical, has received acceptance for its marketing authorization application for injectable nafamostat mesylate. This drug already has similar products available internationally and one domestic first-copy generic on the market. Sales data indicates that injectable nafamostat mesylate generated 442 million yuan in sales in hospitals above Grade II during the first three quarters of 2025. AI
RANK_REASON The cluster reports on a regulatory filing for a pharmaceutical product, which falls under research and development milestones. [lever_c_demoted from research: ic=1 ai=0.1]
- Dongcheng Pharmaceutical
- injectable nafamostat mesylate
- National Medical Products Administration
- Yantai Dongcheng Northern Pharmaceutical
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →